Alpha-MSH (Alpha-Melanocyte-Stimulating Hormone)

1. Overview

Alpha-melanocyte-stimulating hormone (alpha-MSH, also written as alpha-MSH) is an endogenous tridecapeptide neuropeptide and hormone belonging to the melanocortin family. Its amino acid sequence is Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2, featuring both N-terminal acetylation and C-terminal amidation -- post-translational modifications that are critical for its full biological activity and stability [1][5]. With a molecular weight of 1664.88 g/mol and the molecular formula C77H109N21O19S, alpha-MSH is one of the most extensively studied neuropeptides in biomedical research.

Alpha-MSH is derived from the much larger precursor protein proopiomelanocortin (POMC), a 241-amino acid polypeptide that also gives rise to adrenocorticotropic hormone (ACTH), beta-endorphin, beta-MSH, gamma-MSH, and several other biologically active peptides [5]. The processing of POMC into alpha-MSH is tissue-specific and involves sequential cleavage by prohormone convertases PC1/3 and PC2, followed by trimming by carboxypeptidase E and further modifications including acetylation by N-acetyltransferase [1][5]. In the anterior pituitary corticotrophs, PC1/3 predominantly produces ACTH, while in the intermediate lobe of the pituitary and in hypothalamic arcuate nucleus neurons, both PC1/3 and PC2 are expressed, enabling the further cleavage of ACTH into alpha-MSH and corticotropin-like intermediate lobe peptide (CLIP) [5].

First isolated from pituitary extracts in the 1950s, alpha-MSH was initially characterized for its ability to stimulate melanin production and dispersion in amphibian melanophores. Subsequent decades of research revealed it to be a pleiotropic molecule with roles extending far beyond pigmentation -- encompassing appetite regulation, immune modulation, anti-inflammatory signaling, neuroprotection, cardiovascular function, antimicrobial defense, and sexual behavior [2][19][21]. These diverse functions are mediated through a family of five G protein-coupled melanocortin receptors (MC1R through MC5R), of which alpha-MSH activates four (MC1R, MC3R, MC4R, and MC5R) with varying affinities [6][21].

The therapeutic potential of alpha-MSH has been validated through the clinical success of several synthetic analogs. Afamelanotide, a superpotent MC1R agonist, was FDA-approved in 2019 for erythropoietic protoporphyria [15]. Setmelanotide, a selective MC4R agonist, was approved in 2020 for rare genetic obesity disorders [16]. Bremelanotide (PT-141), acting on MC3R/MC4R, was approved in 2019 for hypoactive sexual desire disorder in premenopausal women [19]. These approvals underscore the translational significance of the melanocortin system.

Molecular Weight

1664.88 g/mol

Sequence

Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 (13 amino acids)

Molecular Formula

C77H109N21O19S

Half-life

~10-20 minutes (native form in plasma); rapidly degraded by endopeptidases and exopeptidases

Precursor

Proopiomelanocortin (POMC)

Key Receptors

MC1R (Ki=0.23 nM), MC3R (Ki=31.5 nM), MC4R (Ki=900 nM), MC5R (Ki=7160 nM)

FDA-Approved Analogs

Afamelanotide (2019, EPP), Setmelanotide (2020, genetic obesity), Bremelanotide (2019, HSDD)

Core Pharmacophore

His-Phe-Arg-Trp (residues 6-9)

2. Biosynthesis and Processing

POMC Gene and Protein

The POMC gene is located on chromosome 2p23.3 in humans and encodes the 241-amino acid preprohormone. POMC is expressed primarily in the corticotroph cells of the anterior pituitary, melanotroph cells of the intermediate pituitary lobe, and neurons of the hypothalamic arcuate nucleus. Lower levels of expression occur in the skin (keratinocytes, melanocytes), immune cells, the gastrointestinal tract, and the reproductive system [1][5].

Tissue-Specific Processing

POMC processing is highly tissue-specific and determines which end products predominate:

• Anterior pituitary (corticotrophs): PC1/3 cleaves POMC to produce ACTH(1-39) and beta-lipotropin. Alpha-MSH is not a significant product here because PC2 expression is minimal [5].
• Intermediate pituitary lobe and hypothalamic neurons: Co-expression of PC1/3 and PC2 enables further processing of ACTH into alpha-MSH (ACTH 1-13, acetylated and amidated) and CLIP (ACTH 18-39). Beta-lipotropin is further processed to gamma-lipotropin and beta-endorphin [1][5].
• Skin: Keratinocytes, melanocytes, and other epidermal cells synthesize and release alpha-MSH in response to UV radiation and pro-inflammatory cytokines, establishing a local paracrine/autocrine melanocortin signaling system [1][17][21].
• Immune cells: Monocytes, macrophages, and lymphocytes can produce POMC-derived peptides including alpha-MSH, forming part of the neuroimmune axis [4][12].

Post-Translational Modifications

The conversion of ACTH(1-13) to bioactive alpha-MSH requires two key modifications: N-terminal acetylation (catalyzed by N-acetyltransferase) and C-terminal amidation. Acetylation markedly increases potency at MC1R and extends half-life by protecting against aminopeptidase degradation. Three forms exist: desacetyl-alpha-MSH, monoacetyl-alpha-MSH, and diacetyl-alpha-MSH, with the diacetylated form being the most potent and most abundant in the brain [1].

3. Melanocortin Receptor Pharmacology

Alpha-MSH is a non-selective agonist at four of the five melanocortin receptors. These receptors are all seven-transmembrane-domain G protein-coupled receptors (GPCRs), but differ in tissue distribution, signaling pathways, and functional roles:

MC1R (Melanocortin-1 Receptor)

• Affinity: Ki = 0.23 nM (highest affinity)
• Distribution: Melanocytes, keratinocytes, immune cells (monocytes, macrophages, dendritic cells, neutrophils), endothelial cells, fibroblasts
• Primary signaling: Gs-coupled, activates adenylyl cyclase leading to cAMP/PKA pathway activation
• Functions: Melanogenesis (eumelanin synthesis via MITF transcription factor), UV-induced DNA repair, anti-inflammatory signaling, immunomodulation [6][17][21]
• Clinical significance: MC1R loss-of-function variants are associated with red hair, fair skin, freckling, and increased melanoma susceptibility

MC3R (Melanocortin-3 Receptor)

• Affinity: Ki = 31.5 nM
• Distribution: Hypothalamus (arcuate nucleus), limbic system, peripheral tissues, immune cells
• Primary signaling: Gs-coupled (also couples to Go proteins)
• Functions: Energy homeostasis, feeding behavior modulation, immune regulation, anti-inflammatory actions [6][21]
• Clinical significance: MC3R mutations have been linked to obesity susceptibility in some populations

MC4R (Melanocortin-4 Receptor)

• Affinity: Ki = 900 nM
• Distribution: Widespread in CNS -- hypothalamic paraventricular nucleus (PVN), dorsomedial hypothalamus, lateral hypothalamus, brainstem, cortex, amygdala, spinal cord
• Primary signaling: Gs-coupled (also couples to Go and Gq; signals through PLC-IP3-Ca2+ in addition to cAMP)
• Functions: Central appetite suppression, energy expenditure regulation, sympathetic nervous system activation, sexual function, neuroprotection, cardiovascular regulation [6][21]
• Clinical significance: MC4R mutations are the most common monogenic cause of severe early-onset obesity (approximately 6% of cases); target of setmelanotide and bremelanotide

MC5R (Melanocortin-5 Receptor)

• Affinity: Ki = 7160 nM (lowest affinity)
• Distribution: Widespread peripheral expression -- adrenal gland, adipose tissue, skeletal muscle, exocrine glands, immune cells, skin
• Primary signaling: Gs-coupled, cAMP signal transduction
• Functions: Exocrine gland secretion (sebogenesis), thermoregulation, immune modulation, potentially involved in sexual behavior [6][21]

The Core Pharmacophore

The minimal sequence required for melanocortin receptor activation is the tetrapeptide His6-Phe7-Arg8-Trp9 (HFRW), known as the "core pharmacophore" or "message sequence." This motif is conserved across all melanocortin peptides (alpha-MSH, beta-MSH, gamma-MSH, and ACTH) and is essential for receptor binding and activation [2][19].

Endogenous Antagonist: Agouti-Related Protein (AgRP)

AgRP is the endogenous inverse agonist/antagonist at MC3R and MC4R, produced by AgRP/NPY neurons in the arcuate nucleus. The balance between alpha-MSH (anorexigenic) and AgRP (orexigenic) signaling at MC4R is a fundamental determinant of appetite and energy balance [21].

4. Researched Applications

Pigmentation and Photoprotection

Evidence level: Strong (human clinical trials; FDA-approved analog)

Alpha-MSH is the principal hormonal regulator of constitutive and facultative skin pigmentation. By binding MC1R on melanocytes, it activates the cAMP/PKA pathway, leading to phosphorylation of the CREB transcription factor, upregulation of microphthalmia-associated transcription factor (MITF), and subsequent expression of melanogenic enzymes including tyrosinase, TRP-1, and TRP-2 [17][21]. This drives a switch from pheomelanin (red/yellow, photo-unstable pigment) to eumelanin (brown/black, photoprotective pigment) synthesis.

Beyond melanogenesis, alpha-MSH provides UV photoprotection through pigmentation-independent mechanisms. It directly enhances nucleotide excision repair (NER) of UV-induced cyclobutane pyrimidine dimers in both melanocytes and keratinocytes via an XPA-dependent mechanism. Studies have shown a 59% reduction in thymine dimer formation and over 50% reduction in sunburn cells following alpha-MSH treatment [17].

The alpha-MSH analog afamelanotide (Nle4-D-Phe7-alpha-MSH, marketed as Scenesse) was FDA-approved in October 2019 as a 16 mg subcutaneous controlled-release implant for increasing pain-free light exposure in adults with erythropoietic protoporphyria (EPP). In Phase 3 trials, afamelanotide significantly increased pain-free time in sunlight compared to placebo [15]. It also increases eumelanin production independently of sun exposure.

Anti-Inflammatory and Immunomodulatory Effects

Evidence level: Strong (extensive preclinical; mechanistic studies in human cells)

Alpha-MSH is one of the most potent endogenous anti-inflammatory peptides identified. Its anti-inflammatory actions are mediated primarily through MC1R (and to some extent MC3R) on immune cells and involve multiple converging mechanisms [3][4][7]:

1. NF-kappaB suppression: Alpha-MSH inhibits nuclear translocation of NF-kappaB by preserving its cytoplasmic inhibitor IkappaB-alpha, thereby blocking transcription of a wide array of pro-inflammatory genes. This occurs in a dose-dependent manner and has been demonstrated in macrophages, endothelial cells, and epithelial cells [7].

2. Pro-inflammatory cytokine downregulation: Alpha-MSH suppresses production and release of IL-1beta, IL-6, IL-8, TNF-alpha, IFN-gamma, Gro-alpha, and MCP-1 in various cell types including monocytes, macrophages, neutrophils, and endothelial cells [3][4].

3. Anti-inflammatory cytokine induction: Alpha-MSH upregulates IL-10, a potent immunosuppressive cytokine that further amplifies the anti-inflammatory cascade [3].

4. Adhesion molecule suppression: Alpha-MSH downregulates ICAM-1, VCAM-1, and E-selectin expression on endothelial cells, reducing leukocyte adhesion and transmigration to sites of inflammation [7].

5. T cell regulation: Alpha-MSH inhibits T cell proliferation and shifts the T cell response from Th1 (pro-inflammatory) toward Th2 and regulatory T cell (Treg) phenotypes [4][22].

6. Nitric oxide modulation: Alpha-MSH suppresses inducible nitric oxide synthase (iNOS) expression and thereby reduces production of inflammatory nitric oxide in macrophages and other cell types [8].

These properties have been validated in numerous experimental models of inflammation including contact dermatitis, allergic asthma, rheumatoid arthritis, vasculitis, uveitis, sepsis, and organ ischemia-reperfusion injury [2][3].

Appetite Regulation and Metabolic Effects

Evidence level: Strong (extensive preclinical and human genetic evidence; FDA-approved MC4R agonist)

Alpha-MSH is a critical anorexigenic (appetite-suppressing) signal within the hypothalamic melanocortin system. POMC neurons in the arcuate nucleus of the hypothalamus are activated by leptin and insulin signaling, leading to alpha-MSH release onto MC4R-expressing neurons in the paraventricular nucleus (PVN), ventromedial hypothalamus, and lateral hypothalamus [21].

Key aspects of this appetite-regulating circuit:

• MC4R activation in the PVN: Alpha-MSH binding to MC4R reduces food intake, increases energy expenditure (via sympathetic nervous system activation of brown adipose tissue thermogenesis), and promotes satiety signaling [21].
• Integration with AgRP/NPY: The opposing actions of alpha-MSH (anorexigenic) and AgRP/NPY (orexigenic) at MC4R create a molecular "switch" that determines net feeding behavior. In states of energy deficit, AgRP predominates; in energy sufficiency, alpha-MSH activity increases [21].
• Interaction with dopaminergic reward pathways: Alpha-MSH modulates dopamine transmission in mesolimbic pathways, influencing food reward valuation beyond simple homeostatic hunger [21].
• MC4R and obesity genetics: Heterozygous MC4R loss-of-function mutations are the most common cause of monogenic obesity, affecting approximately 6% of individuals with severe early-onset obesity. Complete MC4R deficiency causes hyperphagia, hyperinsulinemia, and increased linear growth [16][21].

The therapeutic validation of this pathway came with setmelanotide (Imcivree), a selective MC4R agonist approved by the FDA in November 2020 for chronic weight management in patients aged 6 years and older with POMC, PCSK1, or leptin receptor (LEPR) deficiency obesity. In Phase 3 trials, 80% of POMC-deficient patients and 45% of LEPR-deficient patients achieved at least 10% body weight loss, with significant reductions in hunger scores [16]. In February 2026, the FDA expanded the age indication to include children aged 2 years and older. Most significantly, on March 19, 2026, the FDA approved setmelanotide for acquired hypothalamic obesity -- a broader indication affecting adults and pediatric patients aged 4 years and older -- based on the Phase 3 TRANSCEND trial, which demonstrated a placebo-adjusted BMI reduction of -18.4% (setmelanotide group: -15.8% versus placebo: +2.6%) at 52 weeks [24].

Neuroprotection

Evidence level: Moderate (extensive animal studies)

Alpha-MSH exerts neuroprotective effects through multiple mechanisms involving both MC4R-mediated signaling in neurons and anti-inflammatory actions on microglia and astrocytes [9][14][20]:

• Cerebral ischemia/stroke: In rodent models of global and focal cerebral ischemia, alpha-MSH (100-500 mcg/kg) reduced infarct volume, improved neurological outcomes, and decreased inflammatory cytokine expression. These effects were mediated predominantly through MC4R activation [9]. Alpha-MSH was effective even when administered hours after the ischemic insult, suggesting a meaningful therapeutic window.
• Traumatic brain injury (TBI): The C-terminal tripeptide KPV (alpha-MSH 11-13) attenuated brain damage in controlled cortical impact models through combined anti-inflammatory and anti-apoptotic mechanisms, including reduced caspase-3 activation and decreased neutrophil infiltration [14].
• Excitotoxicity: Alpha-MSH protected neurons against kainic acid-induced excitotoxic cell death, reducing neurodegeneration and gliosis while modulating brain-derived neurotrophic factor (BDNF) expression [14].
• Diabetic neuroprotection: Alpha-MSH promoted neurological recovery and reduced cerebral ischemia/reperfusion injury under hyperglycemic conditions through anti-inflammatory, anti-oxidative, and anti-apoptotic mechanisms.
• Neuroinflammation and cognition: Alpha-MSH reversed high-fat-diet-induced hippocampal-dependent memory impairment by reducing synaptic plasticity changes, oxidative stress, and astrocyte reactivity [20].

Nephroprotection

Evidence level: Moderate (animal studies)

Alpha-MSH has demonstrated significant nephroprotective effects in multiple models of kidney injury [10]:

• In murine ischemic acute renal failure, alpha-MSH inhibited renal injury even when administration was delayed 6 hours after the ischemic insult. It acted by suppressing the maladaptive activation of inflammatory and cytotoxic gene programs in renal tubular cells [10].
• Alpha-MSH was effective in the absence of neutrophils, demonstrating direct protective effects on renal tubular cells via melanocortin receptors expressed on tubular epithelium [10].
• In cyclosporine A nephrotoxicity models, alpha-MSH attenuated both tubular cell apoptosis and tubulointerstitial fibrosis.
• The nephroprotective actions involve suppression of both neutrophil and nitric oxide inflammatory pathways implicated in kidney damage.

Cardioprotection

Evidence level: Moderate (animal studies)

Alpha-MSH provides cardiovascular protection through several pathways [23]:

• Ischemia-reperfusion injury: In isolated rat hearts, alpha-MSH significantly improved fractional shortening, ejection fraction, stroke volume, and cardiac output after ischemia-reperfusion, while exhibiting potent antiarrhythmic properties [23].
• Heme oxygenase-1 (HO-1) pathway: The cardioprotective effects are substantially mediated through alpha-MSH-induced HO-1 protein expression and enzyme activity, which provides antioxidant defense via carbon monoxide and biliverdin production [23].
• Coronary vasodilation: Alpha-MSH promotes intensive dilation of coronary vasculature, improving myocardial perfusion [23].
• Diabetic cardiomyopathy: Long-term osmotic mini pump administration of alpha-MSH improved myocardial function in Zucker diabetic fatty rats.

Antimicrobial Activity

Evidence level: Moderate (in vitro studies)

Alpha-MSH functions as an endogenous antimicrobial peptide in barrier organs (skin, gut) [12][13]:

• Antibacterial: Alpha-MSH and KPV significantly inhibit Staphylococcus aureus colony formation, including methicillin-resistant S. aureus (MRSA). At 12 micromolar concentration, alpha-MSH killed 84% of tested MRSA strains within 2 hours. The mechanism involves membrane permeabilization of bacterial cells [12][13].
• Antifungal: Alpha-MSH peptides reduce viability and germ tube formation of Candida albicans at physiological picomolar concentrations. The antifungal effect is mediated in part through increased cellular cAMP in the yeast [13].
• Broad-spectrum activity: Novel alpha-MSH peptide analogs with modified sequences have demonstrated broad-spectrum antimicrobial activity against multiple bacterial and fungal pathogens [12].
• Dual function: The combination of antimicrobial and anti-inflammatory activities in a single peptide positions alpha-MSH as an innate defense molecule at mucosal surfaces where infection and inflammation frequently coexist [12].

Gastrointestinal Protection

Evidence level: Moderate (animal studies; in vitro)

Alpha-MSH provides protection against experimental inflammatory bowel disease (IBD) through both systemic and local mechanisms [8][18]:

• In dextran sulfate sodium (DSS)-induced murine colitis, alpha-MSH treatment reduced fecal blood by over 80%, prevented weight loss, and markedly suppressed TNF-alpha and nitric oxide production in lower colonic tissue [8].
• The C-terminal tripeptide KPV is transported into colonocytes via the PepT1 transporter, where it directly inhibits NF-kappaB activation in intestinal epithelial cells independently of melanocortin receptor signaling [18]. This PepT1-mediated mechanism provides a non-receptor route for anti-inflammatory activity in the gut.
• Recent research has revealed a dual role for alpha-MSH in colitis: it acts on MC5R on hematopoietic stem cells to promote neutrophil differentiation, enhancing pathogen clearance during the acute phase while potentially sustaining inflammation during remission.

Ocular Immunomodulation

Evidence level: Moderate (animal studies; mechanistic studies)

Alpha-MSH plays a constitutive role in maintaining ocular immune privilege [22]:

• Alpha-MSH is naturally present in aqueous humor, where it suppresses T cell activation, IFN-gamma production, and promotes regulatory T cell expansion [22].
• In experimental autoimmune uveitis, alpha-MSH analogs suppressed disease severity comparable to dexamethasone, but through mechanistically distinct pathways that promote self-regulation of the immune system rather than broad immunosuppression [22].
• Local alpha-MSH administration prevented corneal edema, reduced leukocyte infiltration, and limited corneal endothelial cell apoptosis after injury. In corneal transplant studies, alpha-MSH-treated recipients showed 75% allograft survival at 70 days versus 43% in controls [22].
• Alpha-MSH ameliorated dry eye disease by enhancing EGFR expression through PKA-CREB and MEK-Erk pathways in corneal epithelial cells.

Sexual Function

Evidence level: Strong (FDA-approved analog)

The melanocortin system was first linked to sexual function in the 1960s when administration of alpha-MSH caused sexual arousal in rats. Alpha-MSH acts on MC3R and MC4R in the hypothalamus and other brain regions to activate central sexual arousal pathways [19].

Bremelanotide (PT-141, marketed as Vyleesi) is a cyclic heptapeptide analog of alpha-MSH that activates MC3R and MC4R in the central nervous system. Unlike phosphodiesterase-5 inhibitors that act on peripheral vasculature, bremelanotide acts centrally to stimulate sexual desire. It was FDA-approved in June 2019 as a 1.75 mg subcutaneous injection for hypoactive sexual desire disorder (HSDD) in premenopausal women [19]. Clinical trials also demonstrated pro-erectile effects in men with erectile dysfunction.

5. Clinical Evidence Summary

6. Dosing in Research

The following table summarizes doses used in published research studies and approved clinical products. Native alpha-MSH doses apply to preclinical research; clinical dosing data reflects approved synthetic analogs.

7. Pharmacokinetics

Native Alpha-MSH

Native alpha-MSH has a very short plasma half-life, generally reported as less than 10-20 minutes. Degradation occurs rapidly through two primary mechanisms [1]:

1. Endopeptidase cleavage: Chymotrypsin-like proteases cleave the His6-Phe7 bond; prolylcarboxypeptidase (PRCP) cleaves between Val13 and the C-terminal amide. Additional cleavage occurs at the Trp9-Gly10 bond.
2. Exopeptidase degradation: Aminopeptidases and carboxypeptidases further degrade the fragments.

Human pharmacokinetic studies with radiolabeled alpha-MSH showed biphasic disappearance with a rapid first component (t1/2 ~1 minute) and a slower second component (t1/2 ~25 minutes). The rapid degradation has been the primary driver for development of more stable synthetic analogs [1].

Structural Modifications in Analogs

Several strategic amino acid modifications have produced clinically useful, metabolically stable analogs:

• [Nle4, D-Phe7]-alpha-MSH (NDP-MSH / afamelanotide): Replacement of Met4 with norleucine (Nle) prevents oxidative degradation; substitution of L-Phe7 with D-Phe7 impedes chymotrypsin-like proteolysis. This analog is approximately 10-fold more stable in serum and 100-1000 times more potent at MC1R than native alpha-MSH [15][19].
• Setmelanotide: An 8-amino acid cyclic peptide with selective MC4R agonist activity, engineered for daily subcutaneous dosing with a pharmacokinetic profile supporting once-daily administration [16].
• Bremelanotide: A cyclic heptapeptide with MC3R/MC4R agonist activity, administered as a single subcutaneous injection with peak plasma concentrations within 1 hour [19].

8. The KPV Tripeptide Fragment

The C-terminal tripeptide of alpha-MSH -- Lys-Pro-Val (KPV, alpha-MSH 11-13) -- has emerged as a distinct pharmacological entity with significant therapeutic potential [2][18]:

• Anti-inflammatory activity without pigmentary effects: KPV retains the anti-inflammatory potency of full-length alpha-MSH but lacks melanogenic activity, eliminating the unwanted skin-darkening side effect that limits therapeutic use of alpha-MSH and its MC1R-targeting analogs [2].
• Non-receptor mechanism: Unlike full-length alpha-MSH, KPV appears to exert its anti-inflammatory effects primarily through PepT1 transporter-mediated uptake into cells rather than through melanocortin receptor signaling. Once internalized, it inhibits NF-kappaB activation and IL-1beta-mediated inflammatory cascades [18].
• Enhanced stability: KPV exhibits considerably longer half-life than parent alpha-MSH due to its small size and resistance to the endopeptidases that rapidly degrade the full-length peptide.
• Therapeutic applications studied: KPV has been investigated in models of inflammatory bowel disease, dermatitis, allergic inflammation, and as a topical anti-inflammatory agent. Its favorable physicochemical properties may enable development for inflammatory skin, eye, and bowel diseases [2][18].

9. Safety and Side Effects

Native Alpha-MSH

Endogenous alpha-MSH has an inherently favorable safety profile as a naturally occurring peptide. At physiological concentrations, it participates in normal homeostatic regulation of pigmentation, appetite, immune function, and inflammation. No significant toxicity from exogenous administration of native alpha-MSH has been reported in animal studies [2].

Concerns with Synthetic Analogs

Afamelanotide: The most common adverse events in clinical trials were injection site reactions, skin hyperpigmentation (intended effect), nausea, headache, and fatigue. Long-term safety monitoring is ongoing [15].

Setmelanotide: The most frequent adverse events include injection site reactions, skin hyperpigmentation (occurring in nearly all patients), nausea, diarrhea, abdominal pain, and penile erection/sexual adverse events. No serious treatment-related adverse events were reported in Phase 3 trials [16].

Bremelanotide: Common side effects include nausea (40% of patients), flushing, injection site reactions, headache, and transient increases in blood pressure. It is contraindicated in patients with uncontrolled hypertension or cardiovascular disease [19].

Melanotan II (unregulated): This non-selective melanocortin receptor agonist is not approved by any regulatory authority but is widely used illicitly for skin tanning. Serious reported adverse effects include nausea, facial flushing, spontaneous penile erection, new or changing moles, rhabdomyolysis, renal dysfunction, and potential increased melanoma risk due to chronic melanocyte stimulation. Health agencies worldwide strongly advise against its use [21].

Theoretical Concerns

• Melanoma risk: Chronic MC1R activation stimulates melanocyte proliferation and pigmentation. While alpha-MSH/MC1R signaling is generally considered photoprotective, some preclinical evidence suggests that alpha-MSH downstream signaling could potentially promote immune escape in existing melanoma cells. The relationship between exogenous melanocortin agonism and melanoma risk remains an area of active investigation [21].
• Appetite suppression: MC4R agonism can cause unwanted appetite suppression and weight loss in individuals without obesity.
• Cardiovascular effects: Melanocortin receptor activation can transiently increase blood pressure and heart rate through sympathetic nervous system activation.
• Reproductive effects: Long-term effects of melanocortin agonism on reproductive function and fetal development are not fully characterized.

10. Regulatory Status

Afamelanotide (Scenesse): FDA-approved (October 2019) for increasing pain-free light exposure in adults with erythropoietic protoporphyria. EMA-approved (2014) for the same indication. Manufactured by Clinuvel Pharmaceuticals.

Setmelanotide (Imcivree): FDA-approved (November 2020) for chronic weight management in patients aged 6+ years with obesity due to POMC, PCSK1, or LEPR deficiency confirmed by genetic testing. In February 2026, the FDA expanded the approved age range to include children aged 2 years and older. On March 19, 2026, the FDA approved setmelanotide as the first and only therapy for acquired hypothalamic obesity in adults and pediatric patients aged 4 years and older, based on the Phase 3 TRANSCEND trial showing a placebo-adjusted BMI reduction of -18.4% at 52 weeks. EMA-approved (2021); EMA review of the acquired hypothalamic obesity indication began in August 2025. Manufactured by Rhythm Pharmaceuticals.

Bremelanotide (Vyleesi): FDA-approved (June 2019) for hypoactive sexual desire disorder (HSDD) in premenopausal women. Manufactured by Palatin Technologies / AMAG Pharmaceuticals.

Native alpha-MSH: Not approved as a standalone therapeutic agent in any jurisdiction. Available as a research reagent.

Melanotan II: Not approved by any regulatory authority. Classified as illegal or unauthorized for sale in the US, EU, UK, Australia, and most other jurisdictions. Widely available through unregulated online sources.

KPV (alpha-MSH 11-13): Not approved for therapeutic use. Under investigation as an anti-inflammatory peptide. Available through compounding pharmacies and research suppliers in some jurisdictions, though regulatory status varies.

11. Related Peptides

See also: Afamelanotide (Scenesse), Melanotan II, Setmelanotide (Imcivree), KPV (Alpha-MSH C-Terminal Tripeptide), PT-141 / Bremelanotide (Vyleesi)

The melanocortin peptide family includes several therapeutically relevant members and analogs:

• Afamelanotide (Scenesse): A superpotent, long-acting alpha-MSH analog ([Nle4, D-Phe7]-alpha-MSH) with high MC1R selectivity, administered as a subcutaneous implant for photoprotection in EPP.
• Melanotan II: A non-selective cyclic melanocortin agonist that activates MC1R through MC5R, producing tanning, appetite suppression, and sexual arousal. Not approved for human use; significant safety concerns with unregulated use.
• Setmelanotide (Imcivree): A selective MC4R agonist peptide designed for once-daily subcutaneous injection in rare genetic obesity disorders caused by MC4R pathway defects.
• KPV (alpha-MSH 11-13): The C-terminal tripeptide fragment of alpha-MSH that retains anti-inflammatory activity without pigmentary effects, acting primarily through PepT1-mediated uptake rather than melanocortin receptors.
• PT-141 / Bremelanotide (Vyleesi): A cyclic melanocortin agonist acting on MC3R/MC4R that activates central sexual arousal pathways, FDA-approved for HSDD in premenopausal women.

12. References

1. [1] Rousseau K, Kauser S, Pritchard LE, Warhurst A, Oliver RL, Slominski A, et al. (2010). Alpha-melanocyte stimulating hormone: production and degradation. Journal of Molecular Endocrinology. PubMed
2. [2] Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. (2008). Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews. DOI PubMed
3. [3] Luger TA, Brzoska T. (2007). Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Annals of the Rheumatic Diseases. DOI PubMed
4. [4] Catania A, Gatti S, Colombo G, Lipton JM. (2004). Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacological Reviews. PubMed
5. [5] Dores RM. (2018). POMC: The Physiological Power of Hormone Processing. Physiological Reviews. DOI PubMed
6. [6] Mountjoy KG, Robbins LS, Mortrud MT, Cone RD. (1992). The cloning of a family of genes that encode the melanocortin receptors. Science. PubMed
7. [7] Manna SK, Aggarwal BB. (2000). Mechanisms of the antiinflammatory effects of alpha-MSH: role of transcription factor NF-kappa B and adhesion molecule expression. Journal of Immunology. PubMed
8. [8] Rajora N, Boccoli G, Burns D, Sharma S, Catania AP, Lipton JM. (1997). Alpha-MSH modulates experimental inflammatory bowel disease. Peptides. PubMed
9. [9] Giuliani D, Mioni C, Altavilla D, Leone S, Bazzani C, Minutoli L, et al. (2006). Both early and delayed treatment with melanocortin 4 receptor-stimulating melanocortins produces neuroprotection in cerebral ischemia. Endocrinology. PubMed
10. [10] Chiao H, Kohda Y, McLeroy P, Craig L, Housini I, Star RA. (1997). Alpha-melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. Journal of Clinical Investigation. PubMed
11. [11] Maaser C, Kannengiesser K, Specht C, Lugering A, Brzoska T, Luger TA, et al. (2006). Crucial role of the melanocortin receptor MC1R in experimental colitis. Gut. PubMed
12. [12] Singh M, Mukhopadhyay K. (2014). Alpha-Melanocyte Stimulating Hormone: An Emerging Anti-Inflammatory Antimicrobial Peptide. BioMed Research International. DOI PubMed
13. [13] Colombo G, Buffa R, Bardella MT, Garofalo L, Carlin A, Lipton JM, Bhardwaj R, Catania A. (2000). Antimicrobial effects of alpha-MSH peptides. Journal of Leukocyte Biology. PubMed
14. [14] Giuliani D, Ottani A, Neri L, Zaffe D, Grieco P, Jochem J, et al. (2007). Multiple beneficial effects of melanocortin MC4 receptor agonists in experimental neurodegenerative disorders. Neuroscience. PubMed
15. [15] Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, et al. (2015). Afamelanotide for Erythropoietic Protoporphyria. New England Journal of Medicine. DOI PubMed
16. [16] Clement K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, et al. (2020). Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency. The Lancet Diabetes & Endocrinology. DOI PubMed
17. [17] Deangelis M, Forsberg A, Gatti S, et al. (2021). The alpha-melanocyte-stimulating hormone/melanocortin-1 receptor interaction: a driver of pleiotropic effects beyond pigmentation. International Journal of Molecular Sciences. PubMed
18. [18] Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. (2008). PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. PubMed
19. [19] Hadley ME, Dorr RT. (2006). Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. PubMed
20. [20] Bertolini A, Tacchi R, Vergoni AV. (2009). Brain effects of melanocortins. Pharmacological Research. PubMed
21. [21] Perrotta I, Ferraro MF, Ferro G, et al. (2023). Alpha-melanocyte stimulating hormone (alpha-MSH): biology, clinical relevance and implication in melanoma. Journal of Translational Medicine. PubMed
22. [22] Taylor AW. (2018). The role of alpha-MSH as a modulator of ocular immunobiology exemplifies mechanistic differences between melanocortins and steroids. Ocular Immunology and Inflammation. PubMed
23. [23] Giuliani D, Minutoli L, Ottani A, Spaccapelo L, Bitto A, Galantucci M, et al. (2017). Alpha-Melanocyte-stimulating Hormone Induces Vasodilation and Exerts Cardioprotection Through the Heme-Oxygenase Pathway in Rat Hearts. Journal of Cardiovascular Pharmacology. PubMed
24. [24] Rhythm Pharmaceuticals. (2026). FDA Approval of IMCIVREE (setmelanotide) for Patients with Acquired Hypothalamic Obesity. Rhythm Pharmaceuticals Press Release.